Presenter's Information

Akiko Maehara, MD

Country USA
Specialty Interventional Cardiologist
  1. Calcified Nodules in Complex PCI: Are They All the Same and How Should We Treat?
  2. AI for Imaging and Physiology Interpretation
  3. What Is a Vulnerable Plaque? Insights From Invasive Intravascular Imaging
  4. Prediction of Stent Expansion by IVUS and OCT
  5. Reclassification of Vulnerable Plaque Including Intraplaque Hemorrhage, Fissure, Healed Plaque and More
  6. Understanding MINOCA: Lessons and Case Examples from the HARP Registry
  7. Mechanical Issue of Left Main Stenting - Gap, Incomplete Crush, Deformation and More
  8. Year-In-Review: Intracoronary Imaging & Physiology
  9. Prepare & Predict: Role of Intracoronary Imaging for Calcified Lesion PCI
  10. Imaging Guidance for Calcified Lesion PCI
  11. Intravascular Imaging for Guidance of Plaque Modification Strategies in Calcified Coronary Artery
  12. The Role of Imaging in Calcified Lesions
  13. Coronary Imaging Perspective
  14. [Vulnerable Plaque Detection: What Is New in 2018?] NIRS
  15. Prognosis of "Yellow" Plaque In NIRS
  16. OCT-Guided PCI: OPINION, DOCTORS, ILUMIEN-III and ILUMIEN-IV
  17. How IVUS Improve LM and Bifurcation Outcomes?
  18. ILLUMEN-3 and Others: Imaging-Guided PCI Optimization
  19. How May Imaging Help in LM PCI?
  20. Differences in Plaque Morphology and Stability in STEMI, NSTE-ACS and Stable CAD
  21. Lessons from EXCEL IVUS Substudy
  22. Current and Future Imaging Diagnosis of Vulnerable Plaque
  23. New Findings from COLOR Registry
  24. Difference Between Coronary Artery Disease and Peripheral Artery Disease
  25. Clinical Utility of High-Resolution IVUS
  26. Do Malapposition, Stent Deformation and Fracture Link to Worse Clinical Outcome?
  27. Imaging Criteria of Vulnerable Plaques
  28. Vulnerable Plaque Detection by Grayscale IVUS and NIRS
  29. State-of-the-Art in High Resolution IVUS
  30. Clinical Trials by Using NIRS: Clinical Relevance and Prognostic Implication
  31. Beyond IVUS: OCT, NIRS, and Beyond
  32. NIR: PROSPECT II and PROSPECT ABSORB Trial
  33. NIRS-IVUS to Predict Long Term Outcome
  34. NIR
  35. It Is Time for Practical Use of High-resolution IVUS
  36. Role of IVUS and OCT in Left Main PCI
  37. IVUS-Guided PCI: ADAPT-DES and More...
  38. NIR Spectroscopy: Fundamentals and Diagnostic Applications
  39. Beyond IVUS: OCT, NIRS, and Beyond
  40. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - Yes, I Do. It Will Save Lives and Prevent ACS.
  41. Combined IVUS-NIR Spectroscopy: How to Predict Vulnerable Plaque and PCI Outcome
  42. High Resolution IVUS: See the Unseen!
  43. VH-IVUS: Native Vessel and Neointima
  44. IVUS: Pre-intervention and Post-intervention
  45. Various Types of Yellow Plaque Evaluated by NIRS/IVUS Catheter
  46. NIR
  47. IVUS: Postintervention
  48. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Like to Treat
  49. Near Infrared Spectroscopy
  50. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Do
  51. Neoatherosclerosis: Something New or Nothing New?
  52. [Does Morphology Predict Future Events?] Pro: Yes, Insights from PROSPECT
  53. IVUS Guided CTO Intervention
  54. Morphology and Distribution of Left Main and Non Left Main Bifurcation Atherosclerosis
  55. How Are Left Main and Non Left Main Bifurcations Unique: Insights from Imaging
  56. Temporal Stability of Focal Plaques: 2012 Imaging Insights
  57. Optical Coherence Tomography During PCI: A Research Tool or a Valued Clinical Asset?
  58. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] No, >0.80 Is Not Enough.
  59. Application of the 2nd Generation OCT in LM PCI
  60. Angioscopic and VH Characteristics of Culprits in ACS Patients
  61. What Would Be the Optimal IVUS Criteria to Predict Functional Significance?
  62. When and How To Assess Morphology and Function and Why?
  63. Tissue Characterization Using VH-IVUS; Pitfalls and Artifacts
  64. Expert Opinion for IVUS Use in Practice (Several IVUS Registry and PROSPECT Trial)
  65. Cardiovascular Imaging: “When/How/Which Imaging Modality Should We Choose?”
  66. IVUS Interpretation and Measurement: Focusing on What Important
  67. Assessment of Vulnerable Plaque by IVUS and VH-IVUS
  68. Role of MDCT in PCI Planning: Focus on CTO Treatment
  69. Limitations of IVUS: Why We Need Newer Imaging Techniques
Conference Slides
Category